|Co-produced by ProCE and the Society of Infectious Diseases Pharmacists Education Center (SIDPEC).|
The emergence of the novel coronavirus SARS-CoV-2 and the associated disease, coronavirus disease 2019 (COVID-19), has placed extraordinary pressures upon healthcare systems around the world. Healthcare professionals (HCPs) face the challenge of learning enough about COVID-19 to enable them to provide optimal care to patients and continuing to learn over time as new information and best practices evolve. This activity will improve the knowledge and competency of pharmacists and nurses about the stages of COVID-19 and the role disease progression plays in therapeutic options, the safety and efficacy data for monoclonal antibodies for use in COVID-19, and best practices for the use of monoclonal antibodies in patients with COVID-19.
The target audience for this activity is pharmacists, including specialty pharmacists and other pharmacists who care for patients with COVID-19, nurses across the continuum, pharmacy directors, chief pharmacy officers, health plan administrators, health-systems, group purchasing organizations, and other stakeholders in specialty pharmacy.
After completing the activity, participants should be able to:
- Describe the stages of COVID-19, including early disease characterized by virus replication and later stages characterized by hyperinflammation and exaggerated immune response, and the role this plays in potential therapeutic options for COVID-19.
- Evaluate outcomes from clinical trials evaluating the safety and efficacy of monoclonal antibodies for use in COVID-19.
- Implement best practices in the use of monoclonal antibodies in patients with COVID-19 based on current evidence and guidelines.
Jessica K. Ortwine, PharmD, BCIDP
Clinical Assistant Professor
Department of Internal Medicine, University of Texas Southwestern
Infectious Diseases Clinical Pharmacy Specialist
Department of Pharmacy, Parkland Health & Hospital System
Arun Mattappallil, PharmD
Clinical Pharmacist Specialist – Infectious Diseases
Department of Pharmaceutical Services, University Hospital
Release Date: November 30, 2021
Expiration Date: November 30, 2022
ACPE Credit Designation (Pharmacist CE)
This activity is jointly provided by ProCE, LLC and SIDP. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-252-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Arun Mattappallil, PharmD, has disclosed that he has an ownership interest in Relief Therapeutics.
Jessica K. Ortwine, PharmD, BCIDP, has disclosed that she has no conflicts of interest to report.
The planners/managers reported the following relationships:
Petra Cravens, PhD; Jason Everly, PharmD, BCOP, CHCP; Julie Skowronski, MSN, NP; and Jennifer Swanson, PharmD, have no relevant conflicts of interest to report.
ProCE staff members have no relevant conflicts of interest to report.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an educational grant from GlaxoSmithKline.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.